Apogee Therapeutics (APGE) AI Stock Analysis

• Market Cap: $4.64B
• Dividend Yield: N/A
• Average Volume (3M): 815.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: -58.35%
• Country: US
• Employees: 196
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 55,998,604
• 10 Day Avg. Volume: 871,878
• 30 Day Avg. Volume: 815,049
• PEG Ratio: -0.64
• Price to Book (P/B): 5.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.69
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -12.85
• 1Y Price Target: $104.08
• Price Target Upside: 49.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): -4.72
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $74.00 ▲(5.94% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily shaped by strong capitalization and low leverage, tempered by substantial and accelerating losses/cash burn typical of a development-stage biotech. Technical signals are mixed/neutral, while valuation is constrained by negative earnings. A notable positive corporate event (encouraging Phase 1b data and a robust upcoming clinical timeline) provides an upside catalyst but does not fully offset financial burn risk.

Positive Factors

Balance Sheet Strength

A materially stronger equity base and negligible leverage provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing. This reduces near-term solvency risk, supports enrollment and manufacturing spends, and strengthens bargaining power with partners over the next 2–6 months.

Clinical Catalyst and Clear Development Roadmap

Robust Phase 1b PD and safety readouts plus a planned slate of Phase 2 readouts and a H2 2026 Phase 3 start materially de-risks near-term program execution. Demonstrated durability of effect strengthens go/no-go decisions, partner interest, and probability of advancing toward commercialization.

Platform and Cross‑Indication Pipeline

A platform focused on engineered antibodies with cross‑indication signals (dermatology and respiratory) creates structural upside: a successful modality can be repurposed across indications, reducing single‑asset dependency and enhancing long‑term commercial optionality and partner licensing appeal.

Negative Factors

Accelerating Cash Burn

Rapidly rising operating cash outflows materially increase funding needs and shorten the effective runway. Even with strong equity, escalating burn raises the probability of dilutive financings or constrained discretionary spends, pressuring strategic optionality across the next several quarters.

Pre‑Revenue Status and Widening Losses

Absence of product revenue and sharply widening operating losses mean the company must rely on external capital until commercialization. This structural lack of cashflow generation keeps return profiles negative and magnifies downside if clinical setbacks delay timelines.

Dependence on Future Financing / Development Risk

Despite a healthy capital base today, sustained development spend and binary clinical outcomes make future financing likely. That dependence creates dilution risk and can constrain strategic choices, while clinical/regulatory binary events could materially alter the company's long‑term prospects.

Apogee Therapeutics Business Overview & Revenue Model

Company Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

How the Company Makes Money

Apogee Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the successful development and commercialization of its therapies. Additionally, Apogee may earn revenue from selling its developed therapeutics once they receive regulatory approval and are brought to market.

Apogee Therapeutics Financial Statement Overview

Summary

Balance sheet strength is a major offset (low leverage and a much larger equity base), but the company remains pre-revenue with sharply widening operating losses and accelerating cash burn, increasing reliance on future financing until commercialization.

Income Statement

APGE continues to operate pre-revenue (revenue remains $0 from 2022–2025), so profitability is entirely driven by operating spend. Losses are widening materially: EBIT moved from about -$31M (2022) to -$93M (2023), -$217M (2024), and -$286M (2025). Net income was deeply negative in 2022–2024 (with 2025 net income shown as $0 in the provided data), reflecting a business still in heavy investment mode with no commercial offset, which keeps the income statement quality weak despite a strong development-stage profile typical of biotech.

Balance Sheet

The balance sheet is a clear strength. Leverage is very low (debt-to-equity stays roughly ~0.5%–1.7% across 2023–2025, and debt was $0 in 2022), while equity has grown significantly (about $142M in 2022 to ~$904M in 2025), supporting a solid capital base. The main weakness is returns: return on equity is negative in 2022–2024 due to ongoing losses (2025 shows 0% based on the provided net income), so the company is well-capitalized but not yet generating shareholder returns.

Cash Flow

Cash burn is significant and accelerating: operating cash flow declined from about -$16M (2022) to -$75M (2023), -$171M (2024), and -$227M (2025), with free cash flow similarly negative (-$16M to -$233M over the same period). This indicates rising spending requirements and funding dependence until revenue generation begins. A modest positive is that free cash flow generally tracks reported losses closely (free cash flow to net income near ~1 in 2022–2024), suggesting cash usage is broadly consistent with the income statement rather than being driven by large working-capital swings.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	-1.42M	0.00	0.00	0.00
EBITDA	-284.18M	-216.68M	-74.97M	-39.78M
Net Income	-255.84M	-182.15M	-83.98M	-39.78M
Balance Sheet
Total Assets	937.13M	753.95M	401.40M	152.06M
Cash, Cash Equivalents and Short-Term Investments	730.19M	520.65M	395.46M	151.89M
Total Debt	8.85M	11.83M	2.03M	0.00
Total Liabilities	33.25M	37.16M	21.49M	9.98M
Stockholders Equity	903.88M	716.79M	379.91M	142.07M
Cash Flow
Free Cash Flow	-232.60M	-172.33M	-74.93M	-16.43M
Operating Cash Flow	-227.45M	-171.17M	-74.76M	-16.43M
Investing Cash Flow	-179.57M	-300.46M	-273.91M	0.00
Financing Cash Flow	396.49M	495.11M	315.39M	168.32M

Apogee Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 69.85
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APGE, the sentiment is Negative. The current price of 69.85 is below the 20-day moving average (MA) of 71.29, below the 50-day MA of 72.06, and above the 200-day MA of 55.08, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 31.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APGE.

Apogee Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLPG	68 Neutral	$2.13B	5.74	11.16%	―	―	―
APGE	58 Neutral	$4.64B	-17.91	-36.77%	―	―	-58.35%
AGIO	52 Neutral	$1.65B	-3.82	-31.07%	―	36.26%	-158.98%
IDYA	52 Neutral	$2.93B	-26.90	-11.10%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LQDA	49 Neutral	$3.23B	-43.06	-209.33%	―	343.41%	11.91%
OCUL	48 Neutral	$1.85B	-8.55	-71.66%	―	-9.21%	-8.84%

Apogee Therapeutics Corporate Events

Apogee Therapeutics Reports Positive Phase 1b Asthma Results

On January 6, 2026, Apogee Therapeutics reported positive interim results from a Phase 1b trial of its anti-IL-13 antibody zumilokibart (APG777) in 19 adults with mild-to-moderate asthma and Type 2 inflammation, showing a favorable safety profile, robust and durable suppression of FeNO—a key biomarker linked to asthma exacerbations—through at least 16 weeks for all patients and up to 32 weeks in those with longer follow-up, along with encouraging trends in lung function and other Type 2 biomarkers. The company also highlighted cross-indication signals from its APEX Phase 2 atopic dermatitis program, laid out an aggressive 2026 clinical agenda including multiple Phase 2 data readouts, a planned Phase 3 start in atopic dermatitis by the second half of 2026, and an expanded head-to-head Phase 1b trial of its IL-13/OX40L combination APG279 versus Dupixent, positioning zumilokibart as a potential “pipeline-in-a-product” across dermatology and respiratory markets and reinforcing Apogee’s capacity—backed by long cash runway—to move toward a possible 2029 launch in atopic dermatitis and broader expansion in inflammatory and immunology diseases.

The most recent analyst rating on (APGE) stock is a Hold with a $81.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.